Chirality and drugs used to treat psychiatric disorders

Journal of Psychiatry and Neuroscience

Volumn 27, Issue 6, 2002, Pages 401-403

  Baker, Glen B ^a,b   Prior, Trevor I ^a   Coutts, Ronald T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; HYPNOTIC AGENT; MESORIDAZINE; MIANSERIN; MIRTAZAPINE; NEUROLEPTIC AGENT; PAROXETINE; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SULFORIDAZINE; THIORIDAZINE; TRANYLCYPROMINE; VENLAFAXINE; VILOXAZINE; ZOPICLONE;

BINDING KINETICS; CHIRALITY; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TISSUE LEVEL; EDITORIAL; ENANTIOMER; ENZYME BINDING; HUMAN; MENTAL DISEASE; MIGRAINE; NONHUMAN; PHARMACODYNAMICS; PRACTICE GUIDELINE; PSYCHOPHARMACOLOGY; SIDE EFFECT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL DISORDERS; STEREOISOMERISM;

EID: 0036874946     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (28)

1. Coutts RT, Baker GB. Implications of chirality and geometric isomerism in some psychoactive drugs and their metabolites. Chirality 1989;1:99-120.
2. Lane RM, Baker GB. Chirality and drugs used in psychiatry: Nice to know or need to know? Cell Mol Neurobiol 1999;19:355-72.
3. Cahn RS, Ingold CK, Prelog V. The specification of asymmetric configuration in organic chemistry. Experientia 1966;12:81-124.
4. Caldwell J, Wainer IW. Stereochemistry: definitions and a note on nomenclature. Hum Psychopharmacol Clin Exp 2001;16:S105-7.
5. Jamali F, Mehvar R, Pasutto FM. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J Pharm Sci 1989;78:695-715.
6. Evans AM, Nation RH, Sansom LN, Bochner F, Somogyi AA. Stereoselective drug disposition: potential for misinterpretation of drug disposition data. Br J Clin Pharmacol 1988;26:771-80.
7. Lee EJD, Williams KM. Chirality: clinical pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 1990;18:339-45.
8. Tucker GT, Lennard MA. Enantiomer specific pharmacokinetics. Pharmacol Ther 1990;45:309-29.
9. Campbell DB. Selectivity in clinical pharmacokinetics and drug development. Eur J Drug Metab Pharmacokinet 1990;15:109-25.
10. Evans AM. Enantioselective pharmacodynamics of chiral non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 1992;42:237-56.
11. Gibaldi M. Stereoselective and isozyme-selective drug interactions. Chirality 1993;5:407-13.
12. Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharmaceut Sci 2001;4:185-200.
13. Caldwell J. Do single enantiomers have something special to offer? Hum Psychopharmacol Clin Exp 2001;16:S67-71.
14. Wainer IW. The therapeutic promise of single enantiomers: introduction. Hum Psychopharmacol Clin Exp 2001;16:S73-7.
15. Baumann P, Eap CB. Enantiomeric antidepressant drugs should be considered on individual merit. Hum Psychopharmacol Clin Exp 2001;16:S85-92.
16. Leonard BE. An introduction to enantiomers in psychopharmacology. Hum Psychopharmacol Clin Exp 2001;16:S79-84.
17. Hindmarch I. The enantiomer debate: current status and future directions. Hum Psychopharmacol Clin Exp 2001;16:S101-4.
18. Baldwin DS. Unmet needs in the pharmacological management of depression. Hum Psychopharmacol Clin Exp 2001;16:S93-9.
19. Caldwell J. Importance of stereospecific bioanalytical monitoring in drug development. J Chromatogr A 1996;719:3-13.
20. Tucker GT. Chiral switches. Lancet 2000;355:1085-7.
21. Baker GB, Prior TI. Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs. Ann Med. In press.
22. Jellin J. Neurology/Psychiatry. Pharmacist's Letter 2002;18:53.
23. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-6.
24. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychpharmacol 2002;17:95-102.
25. Mitchell PJ, Hogg, S. Behavioral effects of escitalopram predict potent antidepressant activity. In: New research abstracts of the 154th Annual Meeting of the American Psychiatric Association; 2001 May; New Orleans. Abstract NR503. p. 136-7.
26. Montgomery SA, Loft H, Sanchez C Reines EH, Papp M. Escitalopram (S-enantiomer of citalopram). Clinical efficacy and onset of action predicted for a rat model. Pharmacol Toxicol 2001;88:282-6.
27. Papp M., Sanchez C. Escitalopram: potent and rapid in chronic mild stress model of depression. Presented at the annual meeting of the America Psychiatric Association, 2001 May; New Orleans. Abstract NR554.
28. Agranat I, Caner H. Intellectual property and chirality of drugs. Drug Discov Today 1999;4:313-21.